|
|
Organon and Co (NYSE: OGN) |
|
Price: $14.7100
$-0.01 
-0.068%
|
| Day's High:
| $14.77
| Week Perf:
| -5.71 %
|
| Day's Low: |
$ 14.43 |
30 Day Perf: |
-8.8 % |
| Volume (M): |
3,152 |
52 Wk High: |
$ 23.10 |
| Volume (M$): |
$ 46,362 |
52 Wk Avg: |
$18.15 |
| Open: |
$14.64 |
52 Wk Low: |
$13.87 |
|
|
| Market Capitalization (Millions $) |
3,817 |
| Shares
Outstanding (Millions) |
259 |
| Employees |
10,000 |
| Revenues (TTM) (Millions $) |
6,403 |
| Net Income (TTM) (Millions $) |
864 |
| Cash Flow (TTM) (Millions $) |
-18 |
| Capital Exp. (TTM) (Millions $) |
280 |
Organon And Co
Organon and Co is a pharmaceutical company that was founded nearly a century and a half ago in the Netherlands. It has since grown into a global biopharmaceutical company that specializes in developing and manufacturing innovative medicines to improve patients' lives.
The company's name, Organon, refers to the Greek word "organon," which means "tool" or "instrument." This reflects Organon's mission to create tools and solutions to help physicians and healthcare providers feel confident in their treatment decisions.
Organon and Co's focus is on three main areas: Women's Health, Biosimilars, and Established Brands. The Women's Health division focuses on developing and providing solutions for women's health and wellness, including contraception, infertility, and menopause treatments. The Biosimilars division aims to provide access to high-quality, affordable biosimilars, helping to increase patient access to life-saving biologic medicines. The Established Brands division focuses on providing innovative solutions to improve the health and well-being of patients, including treatments for cardiovascular disease, migraine, and schizophrenia.
Organon and Co is committed to advancing science and research to better understand and meet patients' needs. They invest heavily in research and development, focusing on developing innovative medicines and treatments using state-of-the-art technologies.
In addition to its focus on innovative research and development, Organon and Co is committed to social responsibility and sustainability. They have created programs and initiatives to promote health and wellness in underserved communities, reduce their environmental impact, and improve patient access to medicines.
Overall, Organon and Co's mission is to improve patients' lives by providing innovative solutions and treatments that address pressing medical needs. They are committed to advancing science and research, promoting social responsibility, and ensuring patient access to life-saving medicines.
Company Address: 30 Hudson Street, Floor 33 Jersey City 7302 NJ
Company Phone Number: 430-6900 Stock Exchange / Ticker: NYSE OGN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Thu, Oct 31 2024 1:36 PM UTC
FDA Accepts Biologics License Application for HLX14, a Biosimilar to PROLIA/XGEVA, Marks a Significant Move in Osteoporosis Treatment XANGAI, China, and JERSEY CITY, N.J. In a landmark development for the biosimilar landscape, the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA ...
|
| Business Update
Published Tue, Oct 1 2024 12:47 AM UTC
Shanghai Henlius Biotech, Inc., a leading biotechnology company, in collaboration with Organon, a global healthcare company focusing on women?s health, recently announced a significant milestone in the field of oncology treatment options. The Phase 3 clinical trial of the investigational biosimilar Perjeta (pertuzumab), known as HLX11, has successfully met its primary endpoi...
|
| Business Update
Published Mon, Sep 30 2024 4:47 PM UTC
Breaking New Ground in HER2-Positive Breast Cancer Treatment: Henlius HLX11 Competes with Perjeta In the ever-evolving landscape of oncology, the quest for innovative therapeutic options continues to be driven by the challenges faced in treating various forms of cancer, such as HER2-positive breast cancer. Shanghai Henlius Biotech, Inc. (2696.HK), has emerged as a signific...
|
| Business Update
Published Wed, Aug 21 2024 8:27 AM UTC
In a strategic move to enhance its market presence in the area of migraine treatment, Organon (NYSE: OGN), a global healthcare company with a focus on women?s health, has announced the expansion of its commercial agreement with Eli Lilly and Company. As part of this agreement, Organon will become the exclusive distributor and promoter of Emgality (galcanezumab), a medication...
|
| Business Update
Published Tue, Aug 20 2024 4:47 PM UTC
Abstract: Organon, a global healthcare company focused on women s health, is expanding its market presence through strategic partnerships and regulatory breakthroughs. Recently, it has broadened its commercialization agreement with Eli Lilly and Company for the migraine treatment Emgality (galcanezumab) to eleven additional markets. Furthermore, the company has achieved a ...
|
| Per Share |
Current |
| Earnings (TTM) |
3.32 $ |
| Revenues (TTM) |
24.68 $
|
| Cash Flow (TTM) |
- |
| Cash |
2.6 $
|
| Book Value |
1.82 $
|
| Dividend (TTM) |
1.15 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
3.32 $
|
| Revenues (TTM) |
24.68 $ |
| Cash Flow (TTM) |
- |
| Cash |
2.6 $
|
| Book Value |
1.82 $ |
| Dividend (TTM) |
1.15 $ |
|
|
| |
| Nexplanon Implanon NXT |
|
 15.36 % |
of total Revenue |
| Follistim AQ |
|
3.98 % |
of total Revenue |
| NuvaRing |
|
1.45 % |
of total Revenue |
| Ganirelix Acetate Injection |
|
1.64 % |
of total Revenue |
| Marvelon Mercilon |
|
1.83 % |
of total Revenue |
| Jada |
|
1.01 % |
of total Revenue |
| Other Women s Health |
|
2.53 % |
of total Revenue |
| Renflexis |
|
4.55 % |
of total Revenue |
| Ontruzant |
|
1.26 % |
of total Revenue |
| Brenzys |
|
1.71 % |
of total Revenue |
| Aybintio |
|
0.44 % |
of total Revenue |
| Hadlima |
|
2.53 % |
of total Revenue |
| Zetia |
|
5.12 % |
of total Revenue |
| Vytorin |
|
1.64 % |
of total Revenue |
| Atozet |
|
7.9 % |
of total Revenue |
| Rosuzet |
|
0.7 % |
of total Revenue |
| Cozaar Hyzaar |
|
3.73 % |
of total Revenue |
| Other Cardiovascular |
|
1.83 % |
of total Revenue |
| Singulair |
|
5.37 % |
of total Revenue |
| Nasonex |
|
3.98 % |
of total Revenue |
| Dulera |
|
3.03 % |
of total Revenue |
| Clarinex |
|
1.71 % |
of total Revenue |
| Other Respiratory |
|
0.88 % |
of total Revenue |
| Arcoxia |
|
4.36 % |
of total Revenue |
| Fosamax |
|
2.4 % |
of total Revenue |
| Diprospan |
|
2.34 % |
of total Revenue |
| Other Non-Opiod Pain Bone and Dermatology |
|
4.68 % |
of total Revenue |
| Emgality Rayvow |
|
1.83 % |
of total Revenue |
| Proscar |
|
1.45 % |
of total Revenue |
| Propecia |
|
1.77 % |
of total Revenue |
| Other |
|
2.09 % |
of total Revenue |
| U S |
|
25.16 % |
of total Revenue |
| U S Nexplanon Implanon NXT |
|
10.87 % |
of total Revenue |
| U S Follistim AQ |
|
1.64 % |
of total Revenue |
| U S NuvaRing |
|
0.44 % |
of total Revenue |
| U S Ganirelix Acetate Injection |
|
0.32 % |
of total Revenue |
| U S Jada |
|
0.95 % |
of total Revenue |
| U S Other Women s Health |
|
0.88 % |
of total Revenue |
| U S Renflexis |
|
3.54 % |
of total Revenue |
| U S Ontruzant |
|
0.32 % |
of total Revenue |
| U S Hadlima |
|
1.83 % |
of total Revenue |
| U S Zetia |
|
0.13 % |
of total Revenue |
| U S Vytorin |
|
0.06 % |
of total Revenue |
| U S Cozaar Hyzaar |
|
0.13 % |
of total Revenue |
| U S Singulair |
|
0.13 % |
of total Revenue |
| U S Dulera |
|
2.4 % |
of total Revenue |
| U S Clarinex |
|
0.06 % |
of total Revenue |
| U S Other Respiratory |
|
0.7 % |
of total Revenue |
| U S Fosamax |
|
0.06 % |
of total Revenue |
| U S Other Non-Opiod Pain Bone and Dermatology |
|
0.32 % |
of total Revenue |
| U S Propecia |
|
0.13 % |
of total Revenue |
| U S Other |
|
0.19 % |
of total Revenue |
| Int l |
|
74.84 % |
of total Revenue |
| Int l Nexplanon Implanon NXT |
|
4.42 % |
of total Revenue |
| Int l Follistim AQ |
|
2.34 % |
of total Revenue |
| Int l NuvaRing |
|
1.07 % |
of total Revenue |
| Int l Ganirelix Acetate Injection |
|
1.26 % |
of total Revenue |
| Int l Marvelon Mercilon |
|
1.83 % |
of total Revenue |
| Int l Other Women s Health |
|
1.77 % |
of total Revenue |
| Int l Renflexis |
|
1.01 % |
of total Revenue |
| Int l Ontruzant |
|
0.95 % |
of total Revenue |
| Int l Brenzys |
|
1.71 % |
of total Revenue |
| Int l Aybintio |
|
0.44 % |
of total Revenue |
| Int l Hadlima |
|
0.7 % |
of total Revenue |
| Int l Zetia |
|
5.06 % |
of total Revenue |
| Int l Vytorin |
|
1.58 % |
of total Revenue |
| Int l Atozet |
|
7.9 % |
of total Revenue |
| Int l Rosuzet |
|
0.7 % |
of total Revenue |
| Int l Cozaar Hyzaar |
|
3.6 % |
of total Revenue |
| Int l Other Cardiovascular |
|
1.71 % |
of total Revenue |
| Int l Singulair |
|
5.25 % |
of total Revenue |
| Int l Nasonex |
|
3.98 % |
of total Revenue |
| Int l Dulera |
|
0.63 % |
of total Revenue |
| Int l Clarinex |
|
1.64 % |
of total Revenue |
| Int l Other Respiratory |
|
0.19 % |
of total Revenue |
| Int l Arcoxia |
|
4.36 % |
of total Revenue |
| Int l Fosamax |
|
2.34 % |
of total Revenue |
| Int l Diprospan |
|
2.34 % |
of total Revenue |
| Int l Other Non-Opiod Pain Bone and Dermatology |
|
4.36 % |
of total Revenue |
| Int l Emgality Rayvow |
|
1.83 % |
of total Revenue |
| Int l Proscar |
|
1.45 % |
of total Revenue |
| Int l Propecia |
|
1.71 % |
of total Revenue |
| Int l Other |
|
5.06 % |
of total Revenue |
| Europe and Canada |
|
27.56 % |
of total Revenue |
| United States |
|
25.16 % |
of total Revenue |
| Asia Pacific and Japan |
|
16.43 % |
of total Revenue |
| China |
|
13.4 % |
of total Revenue |
| Latin America Middle East Russia and Africa |
|
15.36 % |
of total Revenue |
| |
On October 9 2024 the Organon And Co provided following guidance
nnOrganon and Co. to Announce Third Quarter 2024 Earnings and Host Investor Call on October 31, 2024nn
nnJERSEY CITY, N.J.nn ? Organon (NYSE: OGN), a global leader in healthcare dedicated to women's health, is set to release its financial results for the third quarter of 2024 on October 31, 2024. The company will hold a webcast and conference call that morning at 8:30 a.m. EDT to discuss the results in detail.
In its financial guidance, Organon anticipates incurring a milestone expense of $51 million during the third quarter, which is expected to have a notable effect on the company's earnings. Specifically, this expense is projected to reduce both Generally Accepted Accounting Principles ...
|
|
|
